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Understanding the spatial distribution of prostate cancer and how it changes according
to prostate specific antigen (PSA) values, Gleason score, and other clinical parameters may
help comprehend the disease and increase the overall success rate of biopsies. This work
aims to build 3D spatial distributions of prostate cancer and examine the extent and location
of cancer as a function of independent clinical parameters. The border of the gland and
cancerous regions from whole-mount histopathological images are used to reconstruct 3D
models showing the localization of tumor. This process utilizes color segmentation and
interpolation based on mathematical morphological distance. 58 glands are deformed into
one prostate atlas using a combination of rigid, affine, and b-spline deformable registration
techniques. Spatial distribution is developed by counting the number of occurrences in
a given position in 3D space from each registered prostate cancer. Finally a difference
between proportions is used to compare different spatial distributions. Results show that
prostate cancer has a significant difference (SD) in the right zone of the prostate between
populations with PSA greater and less than 5 ng/ml. Age does not have any impact in the
spatial distribution of the disease. Positive and negative capsule-penetrated cases show a SD
in the right posterior zone. There is SD in almost all the glands between cases with tumors
larger and smaller than 10% of the whole prostate. A larger database is needed to improve
the statistical validity of the test. Finally, information from whole-mount histopathological
images could provide better insight into prostate cancer.
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The prostate is a male sex gland about the size of a walnut located bellow the bladder (the
organ that stores and releases urine) and in front of the rectum. The urethra, the tube that
carries urine from the bladder, passes through the center of the prostate, as shown in Figure
1.1. The prostate is anatomically divided into three zones: peripheral, central and transi-
tional. The peripheral zone comprises the majority of the prostatic volume (approximately
65%). The central zone is the second largest region in the prostate comprising approx-
imately 25% of its volume. The transition zone consists of two lobes that surround the
proximal urethral segment laterally and interiorly [4].
The primary function of the prostate is to secrete an alkaline fluid that constitutes part
of the seminal fluid, which is responsible for carrying the sperm during ejaculation.
The prostate gland tends to increase in size with the years, which can cause the urethra
to become narrower and decrease urine flow, causing pain on patients. Prostate diseases
occur commonly in men over 40 years. Men who suffer from these diseases have urinary
problems that affect their quality of life. The more common benign (non-cancerous) prostate
problems are:
• Benign Prostatic Hyperplasia (BPH) - is the medical term for enlargement of the
prostate gland, BPH is the most common non-cancerous prostate problem, occurring
in most men by the time they reach their 60s. Symptoms are slow, interrupted, or
weak urinary stream. Although it is not cancer, BPH symptoms are often similar to
those of prostate cancer.
• Prostatism - the symptom of decreased urinary force due to obstruction of flow
through the prostate gland. The most common cause of prostatism is BPH.
• Prostatitis - inflammation or infection of the prostate gland characterized by discom-
fort, pain, frequent or infrequent urination, and sometimes fever.
• Prostatalgia - pain in the prostate gland, also called prostatodynia. It is frequently a
symptom of prostatitis.
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Figure 1.1: Anatomy of the prostate gland which is divided into peripheral, central and
transitional zones. The prostate is located bellow the bladder and in front of the rectum.
The cancer occurs when some prostate cells mutate and begin to multiply uncontrol-
lably. They may also spread from the prostate to other parts of the body, especially bones
and lymph node causing metastasis [5].
According to the American Cancer Society the prostate adenocarcinoma remains a dis-
ease that affects most men. The estimated incidence and mortality numbers for 2012 due
to this disease were 241,740 and 28,170 [3]. Prostate cancer is the second most common
cancer among peruvian men [6]. Worldwide the incidence and mortality numbers are ap-
proximately 899,000 and 258,000, respectively. (Web: GLOBOCAN 2008, 2012 [7]).
1.1 Current Medical Procedure
The doctor inserts his finger into the rectum to examine the prostate. The doctor feels tex-
ture, shape or size of the gland in order to find tumors that may be in it. This test is called a
digital rectal examination (DRE). A palpable abnormal nodule (lump or hard knot) and/or
asymmetry may indicate prostate cancer. Although the DRE has a good positive predictive
value [8], few tumors are detected only with an abnormal DRE [9]. A problem with the
DRE is the low reproducibility of the results due to inter-observer variability [9]. The sen-
sitivity of DRE is low: about 17% of men with a normal DRE are diagnosed with prostate
cancer after a biopsy. Because of its low sensitivity, low specificity and high error rate asso-
ciated with the sub-classification, digital rectal examination should not be used as the only
screening method.
Prostate specific antigen (PSA) is a substance in the blood that is produced naturally by
the prostate gland. High levels of PSA (greater than 4 ng/mL for Peru and the USA.) may
be an indication of prostate infection, inflammation, enlargement or cancer.
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Figure 1.2: During a transrectal biopsy, a biopsy gun is inserted through the rectum and
small sections of the prostate glands tissue are removed for analysis. The original image is
from Mayo Foundation for Medical Education and Research [1].
PSA combined with DRE can help identify prostate cancer in its early stages. It is,
however, necessary to perform a biopsy, which is guided by transrectal ultrasound imaging
(TRUS), see Figure 1.2. TRUS is the preferred imaging modality over computed tomogra-
phy (CT) and magnetic resonance imaging (MRI) mainly due to its non-invasive (does not
modify the physical properties of tissue), non-ionizing, and low-cost characteristics. Other
reason for using TRUS is its association with lesions as hypo-echoic nodules located in the
periphery of the gland [10]. However, TRUS images have a low signal to noise ratio (SNR)
and a low contrast; therefore biopsy examinations have a low level of success, the results
depending on the empirical experience of the radiologist. Flaningas et al. [11] showed in
their publication that biopsy tests usually have a success rate around 30% using the six-
core biopsy protocol. Other studies indicate that to increase the level of success more cores
should be taken directly affecting the patient.
It is for this reason that several researchers started building virtual 3D models of the
prostate and simulating prostatic biopsy tests. Different biopsy schemes can be virtually
simulated and evaluated before clinical application. The use of virtual 3D models or proba-
bilistic maps (atlas) is is to the study the areas within the prostate gland where the cncer is
more likely to develop. An estimation of the tumor distribution has a significant impact to
both clinical and academic interests. In Table 1.1 it is summarized the different publications
in prostate biopsy simulation [2].
Different researchers have begun to explore the possibility of using a large number of
histological pictures to develop a probability map containing the tumor distribution within
the prostate gland. This distribution map can be used to study the efficiency of existing
biopsy schemes, or to design optimal biopsy strategies [16, 17, 18, 19, 20, 22, 33].
A key problem involved in this study is the registration of 3D surface models. All
the studied prostate models need to be reshaped, so that tumors are placed in a uniform
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Table 1.1: Published articles of computerized simulation of prostatic biopsy, the original
table is from [2].
References Description Number of prostate
Bauer et al. [12] Sextant (72.6%), 10-core and 12-core (99.0%), 14-
core (99.5%), 5-region (12-core) (90.5%)
201
Bauer et al. [13, 14] Sextant (54.3%), 5-reg (10-core) (100.0%) 35
Zeng et al. [15] Sextant (71.5%), 10-core (96.4%), 12-core (97.2%),
5-reg (12-core) (89.7%)
281
Zeng et al. [16, 17] Zone-based 3D distribution map of prostate cancer
(8-division and 48-division schemes)
281
Shen et al. [18, 19] Deformable registration. Atlas-based optimal
biopsy strategy
64(of 281)
Opell et al. [20] Zone-based 3D distribution map of prostate cancer
(24-division scheme)
281
Sofer et al. [21] Atlas-based optimal biopsy strategy (48-division
scheme)
301
Shen et al. [22] Deformable registration. Atlas-based optimal
biopsy strategy
100
Zeng et al. [23] Correlation between biopsy core volume and tumor
volume
107
Chen et al. [24] Sextant (73%), 10-core (96%). Tumor volume > 0.5
cm3
180(607) a
Chen et al. [25] Ten schemes including 5-reg (18-core) (87%), 11-
core (94%), etc. Tumor volume > 0.5 cm3
180
Chen et al. [26] Sextant (18% when tumor volume < 0.5 cm3, 73%
when tumor volume > 0.5 cm3)
180(607)a
Babaian et al. [27] A 11-core multi-site directed biopsy (sextant plus 3
alternate sites)
183 + 179b
Loch and Chen [28] Computer simulation of prostate biopsy schemes N/A
Daneshgari et al. [29] Sextant scheme. Tumor volume < 6.0 cm3 N/A
Crawford et al. [30] Standard 6-core regarding different criterias of sig-
nificance
59
Kawata et al. [31] Systematic sextant biopsy and laterally directed 6-
core biopsy
86 + 40b
Loughlin et al. [32] Standard 6-core, 10-core (no results presented) N/A
Frimmel et al. [33] Spatial distribution of prostate tumours regarding tu-
mour volume
81
Egevad et al. [34] Impacts of position and direction of 10-core 75
Egevad et al. [35] Evaluate the 3D prostate model, using simulation re-
sults of 10-core biopsy
81
a 607 tumour foci in 208 specimens.
b Data from two different institutions.
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prostate. Some researchers used manual registration of 2D slices (Xuan et al. [36]). Frim-
mel et al. [33] dividing all prostate models into three groups by size (small, medium and
large). Prostate models were reshaped into the shape of one of these three groups using a
2D reshaping algorithm. Shen et al. [18, 19, 22] presented the use of a deformation based
registration approach using an adaptive focus deformable model (AFDM) [37, 38] to spa-
tially normalize the external and internal structures of the prostate samples.
One of the problems with the registration task is the deformation process suffered by
the prostate and the tumor. Zeng and coworkers [16, 17] investigated the spatial distribution
of prostate cancer using a zone-based strategy, rather than deformation-based approaches.
Prostate models were divided into 8 or 48 symmetric zones. First a quick 3D checking was
performed to identify if a cancer is completely inside or outside a zone using the 3D bound-
ing box, then a 2D scan line algorithm was applied to the 2D section planes to identify if the
zone contained cancer. A similar work was proposed by Opell et al. [20], with the number
of zones used equal to 24. However, the result of these works showed cancer distribution in
a limited number of box zones (8-48) rather than anatomic zonal structures.
Frimmel et al. [33], and Shen et al. [18, 19, 22] showed that prostate cancer is mainly
distributed along the periphery of the prostate. Zeng et al. [17] and Opell et al. [20] reported
a significantly higher cancer distribution in the posterior zones than anterior zones.
However, these studies have focused on optimizing biopsy cores, without using other
relevant information such as the PSA level of patients and their correlation with the location
of tumor in the gland. Other parameters such as cancer volume and Gleason score (cancer
grade descriptor) would have some impact on the tumor distribution [39]. Ou et al. pro-
posed to evaluate the cancer significance and help improving the cancer volume estimation
and Gleason Score, two of the most important surrogate markers. This is useful information
for the treatment planning. It is for a better understanding of the disease, concerning its
pathological variables, that the present research develops several probabilistic maps of the
tumor distribution. Having this tool would help create a starting point for future works that
would lead to a better understanding of the relationship between tumor distribution among
different surrogate markers as PSA, Gleason Score, age, capsule penetration, etc.
For example, knowing whether prostate cancer for men under 60 has the same distribu-
tion as for men over 60 would allow different planning for each group. Both atlases would
be analyzed statistically in order to determine if significant differences are found.
To develop the atlas, pathological and histological images will be used. The images
were acquired using a digital camera and provided by University of Rochester, (Rochester,
New York, U.S.A.). An expert radiologist made the segmentation of the tumor on histology
images. We will use various topics of image processing for the creation of the atlas. After
that we will carry out a statistical study of spatial distribution.
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This thesis is distributed as follows: Chapter 2 describes the protocol of image acqui-
sition and definitions of various markers used for selection of different atlas. Chapter 3
describes the methodology to develop the atlas. Chapter 4 describes the statistical method
to differentiate spatial distribution. Results are presented in Chapter 5. Finally, Chapter 6
presents a brief discussion ending with discussion and conclusions.
Chapter 2
Gathering of Histopathological Data
and Images
In order to accomplish the objectives of this research, it is important to build a database
with information from patients that include histopathological variables, pathological and
histological images and 3D reconstruction of the gland.
Histopathological variables are used to understand the spatial distribution of prostate
cancer and how it changes according to clinical parameters in order to comprehend the dis-
ease. The color images from both, gross pathology and histological slices are used to build
a 3D reconstruction of each patient’s gland showing the location of the tumor. Then, with
this information a registration algorithm is used to construct the spatial probability map.
This process is presented in detail in Chapter 3.
Histopathological variables gathered for this thesis are: PSA value at time of the surgery,
Gleason score, T-Stage, capsule penetration, age, percentage of cancer and volume of the
gland.
The federal Health Insurance Portability and Accountability Act (HIPAA) training, in-
formation of the surrogate markers of patients and both pathology and histology images,
were provided by University of Rochester Medical Center (URMC) at Rochester, New York,
USA. An expert radiologist made the segmentation of the tumor on histology images using
blue or black ink color markers.
2.1 Pathological Variables (Surrogate Marker)
2.1.1 Prostate-Specific Antigen (PSA)
The biological function of the prostate specific antigen is liquefying the seminal coagulum
after ejaculation. It can be detected in the blood of all adult men. Elevated levels of PSA in
blood serum are associated with benign prostatic hyperplasia and prostate cancer.
7
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The effectiveness of PSA as a tumor marker has made a significant impact in the man-
agement of prostate adenocarcinoma. PSA was discovered in the 1970s, its application
began in the 1980s, and its widespread usage began in the 1990s. in 1987, Stamey and co-
workers were the first group to perform a clinical study showing the effectiveness of PSA
as a tumor marker in prostate cancer [40].
PSA is secreted into seminal fluid at concentrations of 0.5−3 ng/ml (i.e., about 1 mil-
lion times more than those in plasma). In the USA and in Peru a cutoff level of 4 ng/ml
has become widely used as a decision limit although it does not correspond to any reference
value [41, 42, 43, 44].
The PSA concentrations in serum increase with age [45] and, therefore, the reference
values are age-dependent. For example, in the USA, the level of 2.5 ng/ml is used in the age
group 40−49 years, 3.5 ng/ml at age 50−59 years, 4.5 ng/ml at age 60−69 years, and 6.5
ng/ml at age 70−79 years [45]. The value of using age-specific reference ranges is debated.
The probability of finding a prostate cancer in a man with a serum PSA of 4 ng/ml is about
20% and it is similar when PSA is in the range 2.6−4 ng/ml [45]. So far there is no consen-
sus on which cutoff to use for free PSA and it is furthermore dependent on the assay method.
2.1.2 Gleason Score
Donald F. Gleason introduced the Gleason grading system for prostate cancer used around
the world. Gleason pattern or grading is a microscopic exam based on the glandular archi-
tecture which can be divided into five grades of growth, 5 belonging to the worst prognosis.
The most prevalent and the second most prevalent patterns are graded and added to obtain
a Gleason score [46] which ranges from 2 to 10. Gleason grades are shown as follows:
• Gleason grade 1, very well circumscribed and separate nodules. The glands are small,
well-formed and approximately equal in size and shape.
• Gleason grade 2, the glands are less uniform in size, shape and have more tissue
between them.
• Gleason grade 3, the glands vary in size and shape and are often angular. This is the
most common pattern or grade.
• Gleason grade 4, fused, poorly defined glands. Many cells are invading the surround-
ing tissue.
• Gleason grade 5, the tissue does not have recognizable glands.
2.1.3 T-Stage
To select the treatment of a patient with prostate cancer, the most important marker is the
T-Stage. If the biopsy confirms that cancer exists, more tests should be performed in order
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to determine how far it has spread from within the prostate to nearby tissues or other body
parts. This process is called staging.
Nowadays, there are two classification systems for clinical staging: the Whitmore-
Jewett and the Tumor, Node, Metastases (TNM) classification systems. Whitmore intro-
duced the first clinical staging classification system for prostate cancer in 1956, and Jewett
modified it in 1975.
In URMC the classification system used is the TNM. This system was first adopted
in 1975 by the American Joint Committee for Cancer Staging and End Results Reporting
(AJCC). There are 4 Stages that describe the prostate cancer extension.
The TNM classification applies only to andenocarcinomas. This classification is sum-
marized in Table 2.1.
The TNM system for describing the anatomical extent of the disease is divided in three
components. T is used to describe the extent of primary tumor. N describes the absence or
presence and extent of regional lymph node metastasis. M is used to describe the absence
or presence of distant metastasis [3].
2.2 Database
Our database was comprised of information from patients including clinical parameters
(PSA value at time of the surgery, Gleason score, T-Stage, capsule penetration, age, per-
centage of cancer and volume of the gland), images and 3D reconstructions of the glands.
58 patients consented to participate in this study. All the patients were scheduled to
undergo a radical prostatectomy at the URMC, between 2007 and 2009. Their average age
was 59.8 ± 5.47 years old ranging from 48.5 to 72.8 years old. Their mean PSA value at the
time of surgery was 6.95 ng/ml ± 8.21 ng/ml ranging from 1 ng/ml to 61.1 ng/ml. Their
average Gleason score was 6.84 ± 0.71 ranging from 6 to 9. Their mean prostate weight
was 51.8 g± 11.9 g ranging from 30g to 85g. Their average cancer percentage was 20.71 cc
ranging from 5cc to 60cc.
In the federal Health Insurance Portability and Accountability Act (HIPAA) there are
important regulations governing health insurance coverage protection and health informa-
tion security for Americans and their families. The HIPAA training was taken in order to
guarantee security and privacy of patient information.
CHAPTER 2. GATHERING OF HISTOPATHOLOGICAL DATA AND IMAGES 10
Table 2.1: TNM Staging System, extracted from [3]
Primary Tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Clinically in apparent tumor neither palpable nor visible by imaging
T1a Tumor incidental histologic finding in ≤ 5 % of tissue resected
T1b Tumor incidental histologic finding in > 5% of tissue resected
T1c Tumor identified by needle biopsy (e.g., because of elevated PSA)
T2 Tumor confi ned within prostate α
T2a Tumor involves one half of a lobe or less
T2b Tumor involves more than one half of lobe, but not both lobes
T2c Tumor involves both lobes β
T3 Tumor extends through the prostate capsule
T3a Unilateral extra capsular extension
T3b Bilateral extra capsular extension
T3c Tumor invades seminal vesicle(s)
T4 Tumor is fi xed or invades adjacent structures other than seminal vesicles
T4a Tumor invades bladder neck, external sphincter, or rectum
T4b Tumor invades levator muscles or is fixed to pelvic wall, or both
Regional Lymph Node (N)
NX Regional lymph nodes cannot be assessed
N0 No regional node
N1 Metastasis in single lymph node, ≤ 2 cm
N2 Metastasis in a single node, > 2 cm but ≤ 5 cm
N3 Metastasis in a node >5 cm
Distant Metastasis (M)
MX Presence of metastasis cannot be assessed
M0 No distant
M1 Distant
M1a Nonregional lymph node(s)
M1b Metastasis in bone(s)
M1c Metastasis in other site(s)
α Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is not classified
as T3, but as T2.
β Tumor found in one or both lobes by needle biopsy but not palpable or visible by imaging is
classified T1c.
AUA, American Urological Association; PSA, prostate-specific antigen; TNM, tumor-node-
metastasis.
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Figure 2.1: Anatomic description of the prostate, TZ: transition zone, PZ: peripheral zone,
AFMS: anterior fibromuscular stroma. The original image is from [48].
Figure 2.2: Device used as an external marker of the prostate, the devices was inserted in
the specimen through the apex and the base parallel to the rectal surface of the prostate.The
original image is from [49].
2.3 Image Acquisition Protocol
Prostate specimens were received after radical prostatectomy. Each gland was weighed and
measured. These measurements include apex to base and anterior to posterior dimensions
using calipers (see Figure 2.1 which describes the parts of the prostate), and gland volume.
The gland was inked with different colors representing each quadrant using the CDI tissue
marking dye system (Cancer Diagnostic Inc., Birmingham, MI). A device [47], which con-
sists of two sets of four 3-mm diameter mating metal prongs (see Figure 2.2), was used to
create markers for 3D reconstruction. Each set attached to a metal base in a square grid of
13mm. The prostate was inserted through the apex and the base symmetrically around the
urethra. The specimen then was fixed in 4% formalin for 24 hours.
After fixation, the device was removed and the gland was measured again to assess the
shrinkage factor. The prostate was then sectioned into 4 mm slices from the apex to the
base. Depending on the size of the individual prostate, 6 to 12 gross pathology whole-
mount slices (3 to 5 mm thick) were obtained. The processed whole-section slices were
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embedded in ParaplastT M, using large metal base molds (Surgipath Medical). Sections 45
µm thick were cut from the surface of each block. The slides were baked for 1 hour at 60◦C
and stained using routine hematoxilin-eosin protocol. The result was one histology slide
for each gross slab. The microscope whole-mount sections were examined by an expert
pathologist in order to recognize the tumor in every slice, and then the expert pathologist
outlined the tumor using a marker ink blue or black.
Both gross pathology and histology slices were photographed after preparation, so that
3D reconstruction could be done. The color images both gross pathology and histological
slices were captured using a digital camera (Diagnostic Spot RT digital color camera, Di-
agnostic Instruments Inc, Sterling Heights, MI). The sheets were mounted on a flat table,
parallel to the focal plane of the camera. The distance between the camera and the sheets
was about 30 cm. The images were stored on a computer using the Advanced Spot camera
software (Diagnostic Instruments). For the gross specimens a caliper was used to measure
the thickness of each slice. This measurement was used for 3D reconstruction.Additional
information on the acquisition protocol is given in the article by Taylor et al. [49].
Chapter 3
3D Reconstruction of the Prostatic
Gland (ATLAS)
The methodology followed to create the 3D spatial distribution consists of: first, alignment
of the histological and pathological image of the same prostate; then segmentation the gland
and the tumor in order to have the outlines; followed by interpolation to have an isotropic
volume. For interpolation we use the distance between apex to base of the fresh gland
when it is extracted, that information can be found on the patient info sheet, and finally one
prostate is (selected as the atlas model) used as a reference and the other glands are warped
against it (3D registration). The Figure 3.1 shows the block diagram of the methodology
applied to build the 3D model.
Figure 3.1: Methodology to build the 3D spatial distribution. First align the histological
and pathological image of the same prostate; then segmentation the gland and the tumor;
followed by interpolation to have an isotropic volume using the patient information sheet in
order to get the distance between slices and finally the registration step.
3.1 Alignment
Since pathological and histological images are positioned differently during image acquisi-
tion, it is necessary to have an alignment step. First, all histological and pathological slices
are registered to their respective central slices (fixed images) since they are more likely to
13
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(a) (b)
(c) (d)
Figure 3.2: (a) Label of the four holes in the central histology slice. (b) Device used in the
image acquisition protocol. (c) Next histological cut of the same prostate gland, It is not
aligned with the base image (image a). (d) Result of image b align with the base image.
The four holes in the prostate gland are used as landmarks in the alignment step.
show four holes caused by the marking device. Each hole is labeled clockwise with a num-
ber (see Figure 3.2a) in all slices. This step is performed manually.
The device used in the acquisition protocol provides landmarks which are 13 mm apart
in a square configuration. This information is helpful to correct any deformations which
the tissue underwent as part of the pathology processing. Figure 3.2a shows the four holes
from the landmark device (Figure 3.2b) in a histology slice. Figure 3.2c shows the next
slice from the same prostate. The holes are not positioned in the same place. Finally, Figure
3.2d shows the result after applying the alignment step to the second image.
There are two ways to warp an image [50]. The forward mapping scans through the
source image, pixel by pixel, which copies them to the appropriate place in the destination
image. The second, reverse mapping goes through the destination image, pixel by pixel,
and samples the correct pixel from the source image. In the forward mapping case, some
pixels in the destination might not get painted, and would have to be interpolated. So the
reverse mapping is applied.
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Figure 3.3: Single line pair
In the warping process, a pair of corresponding lines in the source and destination im-
ages define a coordinate mapping from the pixel X in the destination image to the pixel X
′
in the source image. Let’s consider that the landmarks 1 and 4 form the line PQ in the





as we can see in the Figure 3.3.
We calculate the distance of a pixel X to the line PQ obtaining v and the distance from
P to the projection of X onto the line PQ obtaining u; with these values we determine the
location of X
′
in the source image, maintaining the proportions. This procedure is repeated
for all image points. The equations to calculate the new position are:;
u =
〈(X − P), (Q − P)〉
‖ Q − P ‖2
(3.1)
v =
(X − P) ⊥ (Q − P)
















‖ Q′ − P′ ‖
(3.3)
Because there are four holes (four pairs of lines) a position X
′
i is calculated for each pair
of lines. The displacement Di = X
′
i − X is the difference between the pixel location in the
source and destination images, and a weighted average of those displacements is calculated
(see Figure 3.4). Then a weight is assigned to each line which should be strongest when
the pixel is exactly on the line, and weaker the further the pixel is away from it. For more
detail see [51].
Due to the cutting and tearing in the acquisition protocol, some histological images will
have missing parts (see Figure 3.5a). In order to determine a possible border, we propose
to use information from its pathological counterpart. Following the same procedure to align
the set of histology images, the holes in the corresponding pathology images are labeled
and the warping transform is applied.
Pathology images are used when there is missing information in the boundary of the
histological image (see next Section 3.2). In all cases the central slice of the prostate is
selected as the fixed image, and the rest of the cuts are aligned to it.
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Figure 3.4: Multiples line pairs
Histological cuts of the base and apex do not always show all four holes. Since at least
two holes are needed for the warping transformation, when only one hole is present a trans-
lation transform is applied.
3.2 Segmentation
The purpose of the segmentation is to identify the outline of the prostate and the shape of
the tumor previously delimited by an expert pathologist. This segmentation step is required
to generate a three-dimensional reconstruction of the prostate and the tumor.
Since the acquisition environment was not controlled when the digital images were
taken, they have not been exposed to the same lighting conditions producing unwanted
shadows and reflections. Therefore, a pre-processing step is required. The histological im-
ages have a characteristic red to pink color with a white background. Thus, the intensity
levels corresponding to the image are located on the first mode of its histogram. The other
mode corresponds to the background (highest intensity values - near white). The histogram
is formed as the sum of each histograms layer. We detect the peak of the first mount to
establish an upper threshold, whereas the lower threshold is established at the 10% intensity
of the peak as seen in Figure 3.6. Finally, an image stretching transformation [52] is applied
with these two thresholds.
After applying the pre-processing step to the histological images, they show a high con-
trast between the prostate and the background, as seen in the Figure 3.6c. The information
of the prostate gland is located in the red and blue layers; therefore, the segmentation is
obtained using the threshold t for both layers applying the following equation:
BW =
 1, Ir > tandIb > t0, otherwise (3.4)
Where Ir and Ib correspond to the red and blue layers of the histological image after
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(a) (b)
(c)
Figure 3.5: (a) The circle in dark blue in the histological image shows the missing bound-
ary, the black outline is the localization of the cancer, this task is developed by an expert
pathologist. (b) The counterpart gross pathology image of the image a. (c) Gross image
alignment to the histological image, in green the overlay histological.
(a) (b)
(c)
Figure 3.6: (a) Histological cut. The image shows the outline of the tumor and the label R
(right of the patient) also shows unwanted shadows and reflections. (b) Image’s histogram
where L and U are the lower and upper threshold used to stretch the image. (c) Result to
apply stretching transformation to the image a using U and L as limit threshold.
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pre-processing respectively. The threshold value t is not critical since we can select it in a
wide range (150 to 255) with the same result. We set the value to 200. Finally, mathematical
morphology is applied to fill all the possible holes.
The tumor was delineated by an expert pathologist on the histology cut using a blue or
black marker. To segment it from the image, an automated Otsu-based thresholding algo-
rithm [53] was performed on the red layer. After this step, we only consider the objects
which are within the previously segmented prostate.
Some histological images had missing parts (see Figure 3.5a). We propose to use in-
formation from its pathological counterpart to correct the segmented boundary [54].
To do this, we develop a semi-automatic algorithm. First, the pathological and histo-
logical images are aligned as explained in Section 2.2.1 (Figure 3.5c). Then the border
of the segmented prostate is decomposed into a set of vertices, which are overlaid on the
pathology image. A few vertexes are dragged on the desired boundary (pathology image)
by the user.
Then Discrete Dynamic Contours (DDC) [55] are applied to move the rest of the outline
closer to the correct boundary. The vertices inserted by the user (two or three) are clamped,
this produces that adjacent vertices generally deform towards the clamped vertices. The
contour is deformed by moving each of these vertices through a series of iterations accord-
ing to the following kinematic equations:
Pi(t + ∆t) = pi(t) + vi(t)∆t (3.5)
vi(t + ∆t) = vi(t) + ai(t)∆t (3.6)
ai(t + ∆t) =
1
mi
fi(t + ∆t) (3.7)
Where pi = (xi, yi)T is the position of the vertex i; vi(t) and ai(t) are its velocity and
acceleration, respectively; mi is its mass which is assumed to be 1; and t + ∆t represent the
time of the next iteration. The initial velocity and acceleration are set to zero.
The force fi is the result of the sum of three terms:













i are the internal, image and damping forces, respectively; w
int
i
and wimgi are the weight which determine the contribution of each force.
The image forces are determined by
E(xp, yp) =‖ ∆(GσI(xp, yp)) ‖ (3.9)




max ‖ ∆(E(xp, yp)) ‖
(3.10)
Where E(xp, yp) represents the energy associated with a pixel in the image having co-
ordinates (x, y), Gσ is a Gaussian smoothing filter, and I is the image.
The internal force is determined by
f inti = (〈ci, ri〉 −
1
2
(〈ci−1, ri−1〉 + 〈ci+1, ri+1〉))ri (3.11)
ci = di − di−1 (3.12)
ti =
di + di−1






Where di is the unit edge vector from vertex i to vertex i + 1 and ti is tangential unit
vector associated with the vertex Vi.
The damping force is proportional to the velocity vi at the vertex. f di = −0.5vi
We develop a semi-automatic algorithm. First, the pathological and histological images
are aligned as explained in Section 2.2.1 (Figure 3.5c). Then the border of the segmented is
decomposed into a set of vertices, which are overlaid on pathology image. A few vertexes
are dragged on the desired boundary (pathology image) by the user.
This algorithm proposes is semi-automatic, therefore it is always subjective however
DDC makes it easier the segmentation and edit it. In our experiments, the weights are
winti = 0.6 and w
img
i = 0.4. The image force is responsible of moving the vertex to the
nearest and strongest edge as long as it is within the influence area which is determined by
a two-dimensional Gaussian function. Internal forces are computed based on neighboring
vertices and constrain the vertex to form a smooth contour. The damping force provides
stability in the iteration process.
In addition to this problem, in some images, the pathologist did not completely delin-
eate the tumor with a continuous solid line but with spaced dots (Figure 3.7a). To obtain
the complete outline, cubic interpolation was applied (Figure 3.7b).
3.3 Measurement in Gross Pathology
To build the three-dimensional reconstruction of the prostate gland, it is necessary to quan-
tify the separation between histology and gross pathology slices. The thickness of each
gross pathology slab is measured using a caliper. Eight measurements are performed, two
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(a) (b)
Figure 3.7: (a) The outline of the tumor was done using spaced dots. (b) Cubic interpolation
was applied in order to obtain the complete outline.
Table 3.1: Measurement of Gross Pathology (mm)
AL: Apex Left, AR: Apex Right, PL: Posterior Left, PR: Posterior Right.
Pearson 1 Person 2
Slice AR AL PR PL AR AL PR PL
Method 1 - Inside 3.4 2.7 3.2 3.3 2.4 1.9 1.6 2.4
Method 2 - Outside 2.3 2.3 3.1 2.1 3.2 3.6 2.5 3.0
measurements per hole (one using the outside jaws and the other using the depth probe of
the caliper, see Figure 3.8). This task is repeated by two observers and the average measure
is utilized.
Table 3.1 shows the measurements obtained using both methods - outside jaws and the
depth probe of the caliper, all the measures are in millimeters, the average is obtain for all
readings to reduce measurement error. The result will be the distance between histology
cuts.
The gland is subject to various handling during the acquisition process causing it to
shrink or deformed, that is why one of the measurements taken when the prostate is re-
moved is the distance between the apex and the base of the gland. This information is
available in the patient information sheet and it was contrasted with the total distance ob-
Figure 3.8: Measure internal and external by the use of the outside jaws and the depth probe
in each holes, where AL: Apex Left, AR: Apex Right, PL: Posterior Left, PR: Posterior
Right.
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tained after the measurements using the caliper. Therefore, thickness values are scaled to
make the sum of the thickness of all slices equal to the apex-to-base distance measured in
the fresh prostate. Then, an interpolation step is required in order to have a coherent 3D
reconstruction.
3.4 Interpolation
The distance between adjacent image elements (pixels) within a slice is smaller than the dis-
tance between adjacent image elements in two neighboring slices. Histology images have a
thickness of 5 µm and are separated by 4 mm. Therefore, there are 8 frames by patient on
average. In such situations, it is necessary to interpolate additional slices in order to obtain
an isotropic volume.
There are several approaches for reconstructing and displaying 3D objects from serial
cross sections [56], [57], [58]. The major difference of these approaches lies in the inter-
polation method employed. The two main categories of interpolation techniques for recon-
structing objects are: grey-level and shape-based interpolations. Grey-level interpolation
methods employ nearest-neighbor, linear or polynomial and splines interpolation. On the
other hand, shape-based interpolation methods consider shape features extracted from the
image. Shape-based interpolation converts binary images into distance maps using distance
transformation functions such as Manhattan or city-block distance template [59, 60, 61] to
approximate the Euclidean distance between the pixel and the contour of the object. Shape
based interpolation is quite simple to understand, easy to implement and computationally
fast. However, this method fails to interpolate slices when there is no overlapping area be-
tween the two objects.
For example, the Figure 3.9 shows the initial (Figure 3.9a) and last position (Figure
3.9e) of one object (there is not overlapping area between them) and three images added as
result of apply Shape-based interpolation. We can observer that the central image (figure
3.9c) will not have any information of the object. Giving the impression that there are two
objects, not one.
We used the method proposed by Lee and Wang [62] to overcome this limitation. A
morphology-based interpolation method uses dilation and erosion morphological operators
to create distance maps and perform the interpolation.
Before interpolation, it is necessary to align the objects (prostate slices) using their cen-
troids. Then, for two aligned objects, there will be three possible regions, as seen in the
Figure 3.10. We apply a dilation operator to regions I and II which represent the mor-
phological difference between the two objects. The purpose of this step is to obtain the
dilation-based distance to the boundary of region III (intersection of the two objects). After
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Figure 3.9: Result of applying shape based interpolation between (b) and (e) , both images
have not overlapping area between them, given the impression that there are two objects:
(a) - (b) and (d)-(e).
Figure 3.10: The region I and II are the morphologic difference between two objects after
centralization. Color red object one, color black object two.
this, we can apply an erosion operator to interpolate the results. During interpolation, each
pixel in both regions I and II will gradually move toward region III. For more detail of the
kernel used in the dilation and erosion operators, the reader is directed to [62].
After interpolating the prostate, the same procedure is repeated for each tumor present
in the gland. However, there are additional considerations to be taken in order to avoid
ambiguities in the reconstruction. For example, Figure 3.11a, 3.11b and 3.11c shows the
location of tumor in three slices, and in the Figure 3.11d and 3.11e their possible three-
dimensional reconstruction. As we can see there is more than one option, since the tumor
can grow in any direction and sense.
The first consideration is to determine tumor matching between slices since multiple
cancers may exist on two input slices, for that purpose if the distance between the contours
of the tumor was less than 5 mm then they correspond to the same cancer. This a heuristic
based on the experience of the specialist. [63, 64].
The other decision rule is to create a pseudo-cancer by setting a small region in between
two slides, one slide with tumor presence, and the other without it (Figure 3.12a). The
pseudo-cancer is the resulting area of applying morphology erosion to the image right be-
fore there is no presence of tumor (Figure 3.12b).
We perform cancer-to-cancer interpolation and prostate-to-prostate interpolation, in sep-
arate steps. Finally, it is necessary to compensate the effects of centralization by trans-
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(d) (e)
Figure 3.11: (a), (b) and (c) show the location of tumor in three consecutive slices, if there
is not a rule of decision, there will be two possible 3D reconstruction (d) and (e).
(a) (b)
Figure 3.12: Since the thickness of the gross pathology images (4−5 mm) the tumor ends
are not displayed. (a) Shows the tumor in one slice, in the next slice this information is
missing. To make the 3D reconstruction, we insert a pseudo-cancer in between two slides,
as show in (b) . The pseudo-cancer is the resulting area of applying morphology erosion to
the image right before there is no presence of tumor.
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Figure 3.13: Block Diagram of the Morphology-Based Interpolation.
lating the interpolated object back to the correct position, computing the new centroid.
Morphology-based interpolation can be schematized as shown in Figure 3.13.
Figure 3.14 shows the result obtained applying morphology based interpolation to the
prostate gland and tumor. In the first row there are two histological prostate cuts, a physician
expert outlined the tumor with a black marker ink. The first and last column of the second
and last row show the segmented images of the gland and tumor segmentation respectively,
between them we have added two slices by interpolation as described above. Each tumor
matched is represented with a different color which indicates that it is the same tumor.
3.5 Registration
The registration process is composed of four steps. 1) A rigid registration is used to align
the volumes. 2) An affine transformation allows compensation for shear and scale. 3) A
deformable Bspline registration [65] with a coarse grid is applied and 4) Another Bspline
registration with a finer grid. Rigid and affine transformations bring the registration pro-
cess close to its global minimum, and B-spline transformations are used to compensate for
deformations in the gland due to mechanical and chemical procedures in the histological
processing. This approach is evaluated in [66].
Since our database is formed by whole prostatectomy gland subsequent to diagnosing
of cancer; we do not have a healthy prostate and set as a model for the development of the
atlas. Therefore, one prostate with average size and shape is selected manually to be the
atlas model and the 3D reconstructions of the other glands are warped against it.
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(a) (b)
(c) (d) (e) (f)
(g) (h) (i) (j)
Figure 3.14: (a) and (b) corresponding to a histological prostate cuts which shown the
location of the tumor in black color (outline by a pathologist); (c) and (f) shows the gland
segmentation of histological images (a) and (b) respectively; (d) and (e) are the result of
interpolation, added two slices between them; (g) and (j) shows the tumors segmentation
of the images (a) and (b) respectively; (h) and (i) show the tumor interpolation. Each color
indicates the same tumor.
Chapter 4
Statistical Analysis
Once all the prostate glands have been registered into a unique atlas model, the spatial distri-
bution is developed by counting the number of occurrences in a given position in 3D space
from each registered prostate reconstruction.
A group of medical specialists in the field, determined to perform the analysis to the
following spatial distributions:
• PSA at the time of the surgery less than and greater than or equal to 4 ng/ml.
• Age less than and greater than or equal to 60 years old.
• Capsule penetration positive against negative.
• Gleason score equal to 6 against over than 6, and tumors larger and smaller than 10%
of the whole prostate.
The effectiveness of PSA as a tumor marker has made a significant impact in management
prostate adenocarcinoma. In the USA and Peru a cutoff level of 4 ng/ml has become widely
used as a decision limit although it does not correspond to any reference value.
Prostate cancer is a slow-spreading disease, so the diagnosis of this disease usually oc-
curs in men over 40 years, this cutoff level is suggested for early detection [45], men older
than 60 years usually show an advanced disease, however an interesting point of analysis is
to determine whether there is any particular distribution to men under this threshold, since
people with this disease have shown more aggressive cancer compared to over 60 years.
The Gleason score of 6 is the most typical score. Gleason score greater than 6 indicates
that prostate cancer is detected at later stages; understanding the spread of disease or the
areas where it is more aggressive could give a better understand of this disease.
Capsule penetration indicates if the cancer is contained by the capsule that surrounds
the prostate (negative capsule penetration), or if it has spread outside the gland (positive
capsule penetration). Identify region of the prostate with significant difference between
26
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Table 4.1: Inferential Statistical Test
Number of samples Hypothesis evaluated Test
Interval/Ratio Data
Single sample
Hypothesis about a population
mean
• The single-sample z test
(σ known)
• The single-sample t test
(σ unknown)
Hypothesis about a population
parameter/characteristic other
than the mean
• The single-sample chi-






• The t test for two inde-
pendent samples




Hypothesis about a population
median or the distribution of
data in a single population








medians, or some other
characteristic of two
independent populations
• The Mann Whitney U
test
• The Kolmogorov




Hypothesis about distribution of
data in a single population
• The chi-square
goodness-of-fit test
• The z test for a popula-
tion proportion
• The chi-square test of
independence
Two independent samples
Hypothesis about distribution of
data in two independent
populations
• The chi-square test for
homogeneity
• The Fisher exact test
• The z test for two inde-
pendent proportions
Two independent samples Hypothesis about distribution of
data in two dependent popula-
tions
• The McNemar test
positive and negative capsule penetration will be useful to understand the disease and have
an appropriate treatment.
Table 4.1 shows the most common statistical tests used [67]. To select the appropriate
inferential statistical test, the following protocol is followed.
1. State the general hypothesis that is being evaluated.
2. Determine if the study involves a single sample or more than one sample.
3. If there is more than one sample, determine how many samples there are and whether
they are independent or dependent.
4. Determine the level of measurement represented by the data that are being evaluated
(which represents the dependent variable in the study). The level of measurements is:
interval/ratio or ordinal/rank-order or categorical/nominal.
We propose to use the Z-test [67] for subgroup pairs to analyze differences distribution
between two populations where each population has a common pathological variable. The
Z-test for two independent proportions is most commonly employed to evaluate the null and
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alternative hypotheses that are described for the Fisher exact test.
The use of Z-test for two independent proportions is valid since we want to evaluate the
hypothesis about distribution of data in two independent populations which are assumed to
have normal distribution [67]. The alternative hypothesis is that proportions are different,
this is a non-directional alternative hypothesis, and it is evaluated with a two-tailed test.
Null Hypothesis :
H0 : π1 = π2 (4.1)
where π1 and π2 are the population proportion 1 and 2 respectively.
Alternative hypotheses :
H0 : π1 , π2 (4.2)
The following equation is employed to calculate the test static
Z =








• n1 represents the number of persons in one of the populations.
• n2 represents the number of persons in the other populations.
• p1 represents the proportion of the first population, It is employed to estimate the
population proportion π1
• p2 represents the proportion of the second population, It is employed to estimate the
population proportion π2
The proportions are defined as the number of occurrences divided by total number of
patients that correspond to the population of study and analysis (e.g., fifty-eight if we ana-
lyze the entire population, see Figure 4.1).
The difference between proportions is applied to each voxel and is evaluated with a
Z-test in order to ensure that the voxel is significantly different between the two spatial
distributions; this process is repeated for all the voxels corresponding to the prostate atlas
model. We use the critical Z value for two tails 1.65 (equivalent to p = 0.1) in order to find
significant difference (SD).
Table 4.2 shows the number of patients by pathological variable using the threshold
suggested by the physician. In the case of Gleason score, there are not enough patients in
the group where Gleason score = 6 to perform a valid statistical evaluation. Similarly with
PSA lest than 4 ng/ml.
CHAPTER 4. STATISTICAL ANALYSIS 29
(a) Patient 1 (b) Patient 2
(c) Spatial distribution
Figure 4.1: Spatial distribution employing two patients; for each patient the color yellow and
cyan represents the zones with and without tumor, respectively. The value of one and zero
is assigned to the yellow and cyan zone, respectively. To generate the spatial distribution
we count the number of occurrence after sum the two images. The color red corresponds to
two occurrences.
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> 10% of the whole prostate 28
, 10% of the whole prostate 30
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Table 4.3 shows the number of patients by pathological variable with the threshold used
in this research.
The values chosen as threshold in each parameter is compromise between commonly
accepted clinical thresholds separating high and low values, and the number of patients in
each subgroup required to make a good statistical evaluation.
The value used for PSA analysis is 5 ng/ml; in order to obtain representative statistical
analysis (both populations of 29 patients). There is no report in the literature about the exact
cutoff values for PSA.
Another statistical analysis is performed to obtain a better idea of significant difference
by region and not global, for that we divided the prostate into a grid of 12 zones that are
identifiable and accessible by physician (urologist). The grid has three transverse layers
along the (patient’s) vertical axis: base, middle and apex. Each layer is divided into two
coronal layers from the rear to the front, denoted by posterior and anterior. Finally the lay-
ers are divided from left to right into 2 sagittal layers, left and right (see Figure 4.2).
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Figure 4.2: A prostate models with 12 zones division, and his three views
Chapter 5
Results
The database consist of 58 prostates gland and the PSA information, capsule penetration,
patient age, and percentage of cancer. Figure 5.1 shows the cancer probability distribution
of the complete database. The result shows that the prostate cancer is more likely to occur
in the right zone of the prostate. We used a color map in order to facility the zones with
more level of occurrences, the color scale indicates the number of occurrences for a given
population.
Statistical analysis shows that for population with PSA greater and less than 5 ng/ml,
they have the spatial significant difference (SD) in the right zone of the prostate. Figure 5.2
shows the two spatial distributions and their SD. Similar results for population with positive
and negative capsule penetration were obtained (Figure 5.4). In the case of populations
older and younger than 60 years old, Statistical analysis shows that age does not have any
impact in the spatial distribution of the disease. See Figure 5.3.
Figure 5.5 shows the spatial distributions for tumors larger and smaller than 10% of the
whole prostate. There is SD in almost all the gland between cases with tumors larger and
smaller than 10% of the whole prostate (see Figure 5.6d).
For all the cases we used Z-test for two independent proportions, the critical value is Z
= 1.65. In all the cases the red color indicates SD.
The Table 5.1 shows the amount of significant difference in percentage of the whole the
prostate for different cases of study. It is appreciated that values of SD for the whole prostate
are quite low. Even though, there are areas of SD in the different cases being evaluated, Ta-
ble 5.1 show the percentage of these regions over the whole gland is small. In Figure 5.6,
the reader can appreciate that regions without SD are more common that regions with SD.
Therefore, in order to get a better idea of SD in space, we propose an analysis 12 zones of
the prostate. The Table 5.2 and 5.3 show the amount of significant difference by twelfth
zones for different cases of study.
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Figure 5.1: Spatial distribution of all the patients (58 patients), the color scale indicate the
number of occurrences, the right zone shows to have the most level of occurrences.
Table 5.1: Significant difference in the whole prostate according to the case of study
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10% of the whole prostate
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Figure 5.2: The cancer probability distribution for PSA at the time of surgery. (a) greater
than 5 ng/ml / number of patients = 29/58. (b): PSA less than or equal to 5 ng/ml / number
of patients = 29/58, where color scale indicate number of occurrences, the label right, left,
apex and posterior is related to the patient’s position. (c): significant difference (SD) using
Z-test for two independent proportions. The red color indicates SD.




Figure 5.3: The cancer probability distribution according to the age. (a) Older than 60 years
old / number of patients = 33/58. (b) Younger or equal than 60 years old/ number of patients
= 25/58, where color scale indicate number of occurrences, the label right, left, apex and
posterior is related to the patient’s position. (c) significant difference (SD) using Z-test for
two independent proportions. The red color indicates SD.




Figure 5.4: The cancer probability distribution for capsule penetration. (a) pT3 negative
/ number of patients = 34/58. (b) pT3 positive/ number of patients = 24/58, where color
scale indicate number of occurrences, the label right, left, apex and posterior is related
to the patient’s position. (c) significant difference (SD) using Z-test for two independent
proportions. The red color indicates SD.




Figure 5.5: The cancer probability distribution for cancer percentage. (a) greater than 10%
of whole prostate /number of patients = 28/58. (b) less than 10% of whole prostate/ num-
ber of patients = 30/58. (c) significant difference (SD) using Z-test for two independent
proportions. The red color indicates SD.
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(a) PSA > 5 (b) PSA ≤ 5
Figure 5.6: The region in red does not provide much significant difference, the amount of
occurrences is very similar, so the analysis is performed by twelve zones in order to get a
better idea of significant difference in space.
The data in Table 5.2 shows that PSA at the time of the surgery > and ≤ 5 ng/ml has
most significant difference in the anterior and mid zone and less SD in the base. Similarly
there is most SD in the anterior than in the posterior, and right than left zone. The zones with
most SD are apex anterior right and mid anterior right zone, and less SD is base posterior
left zone. For older and younger than 60 years old there is not any zone with a significant
difference. All the zones are less than 17%.
The data in the Table 5.3 shows that for positive and negative capsule penetration the
zones with SD are base and mid right, the zone with most SD is base anterior right (77.71%
of SD). The zone with less SD is the left posterior. For patients with greater and less than
10 percentage of cancer, the zone with less SD is the base posterior left.
Figure 5.5 shows the two spatial distributions for patients with greater and less than 10
percentage of cancer. For patients with less than 10% of cancer, we can see that the largest
amount of occurrence is given in the posterior left zone.
Table 5.2: The amount of significant difference by twelve zones for PSA > 5 vs PSA ≤
5 (Left) and older and younger than 60 years old (Right) population. Where the first A is
Apex, M is Middle, B is Base, second A is Anterior, P is Posterior, R right and L is Left of
the patients.
AAR APR AAL APL
50.87% 23.5% 30.12% 7.84%
MAR MPR MAL MPL
50.2% 32.81% 21.78% 18.54%
BAR BPR BAL BPL
34.26% 31.76% 11.18% 4.2%
PSA>5 vs PSA ≤ 5
AAR APR AAL APL
3.91% 10.88% 3.09% 18%
MAR MPR MAL MPL
1.88% 6.76% 1.27% 8.08%
BAR BPR BAL BPL
5.74% 8.72% 17.23% 5.28%
Age>60 vs Age ≤ 60
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Table 5.3: The amount of significant difference by twelve zones for positive and negative
capsule penetration (left) and greater and less than 10 percentage of cancer (right) popula-
tion. Where the first A is apex, M is middle, B is base, second A is anterior, P is posterior,
R right and L is left of the patients.
AAR APR AAL APL
8.26% 10.88% 8.49% 7.8%
MAR MPR MAL MPL
40.25% 32.16% 8.89% 5.32%
BAR BPR BAL BPL
77.71% 33.21% 38.38% 3.96%
Positive and negative capsule penetration
AAR APR AAL APL
41.74% 78.4% 1.54% 75.23%
MAR MPR MAL MPL
84.68% 98.26% 40.89% 69.23%
BAR BPR BAL BPL
92.06% 88.53% 62.69% 28.75%
Greater and less than 10% of cancer
Chapter 6
Discussion and Conclusions
Probabilistic maps are used to investigate where it is more likely to develop cancer within
the prostate gland. The goal of this thesis is to develop a computational tool which extends
the use of probabilistic maps for a statistical analysis of prostate cancer between different
populations in relation to its clinical parameters: PSA, capsule penetration, age of the pa-
tients and cancer percentage. This analysis provides spatial significant differences between
maps which would increase our understanding of this disease in relation to its clinical pa-
rameters. This tool would help create a starting point for future works to comprehend the
relationship between tumor distributions and different surrogate markers. Therefore, this
study could have a significant impact in academic research.
Several computer-assisted approaches [12, 14, 17, 18, 19, 20, 21, 22, 24, 27, 34, 35]
developed in this field have been focused on the maximization of the probability that biopsy
needles intersect with the tumor and the improvement of cancer detection without consider-
ing other clinical parameters. This tool can estimate spatial distribution of the cancer using
clinical parameters which have a significant impact on clinical research, with the addition
of clinical parameters is possible to have a probabilistic map customized by patient.
Histopathological images were used to create the spatial distribution of prostate cancer.
Pathology experts outlined the location of the cancer on the image. The distance between
the cuts was between 4mm and 7mm, so it required an interpolation step in order to have an
isotropic volume. However in the specialized literature [12, 14, 17, 18, 19, 20, 21, 22, 24,
27, 34, 35] a criterion has not yet been established for the reconstruction of the tumor, since
it can grow in any direction and orientation (see Figure 3.11). In this work, two decision
rules were introduced in order to avoid ambiguities in the reconstruction of the tumor (see
chapter 3, section 4).
The database has been formed by glands after whole prostatectomy with a cancer di-
agnosis. Consequently, the database has not got a healthy prostate, and the probabilistic
model has some deformation because of the presence of a tumors. An expert pathologist
manually selected one prostate from the database with an average size and shape to be the
atlas model. This process is similar to other reported studies [18, 19, 22, 39], and does not
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affect the statistical analysis used since the same prostate is used for the registration step.
Most of the statistical analyses are based on the hypothesis about two independent pop-
ulation medians (The Mann-Whitney U test and Kolmogorov-Smirnov test for two inde-
pendent samples) which perform a comprehensive analysis of the distributions indicating
the similarity between populations. However these analyses do not give spatial difference
between two populations. The Z-test for two independent proportions was proposed in or-
der to determine the most significant difference voxel by voxel. We analyze differences in
distribution between two populations where each population has a common pathological
variable.
These analyzes give an overall comparison of the distribution between two populations
without knowledge of spatial location. The goal in this thesis is to develop a spatial analysis
in order to determine the most significant difference in a voxel by voxel basis.
During the development of this thesis, a number of questions have appeared based on
the results. For example, why is prostate cancer more likely to appear to the right of patient?
Previous studies on 3D spatial distribution of prostate cancer [15, 16, 17, 18, 19, 20] have
shown agreement with the results obtained in this work. The area with the highest number
of occurrences is the right zone, more accurate in the right posterior peripheral zone near to
the base of the prostate. This result confirms the medical knowledge gained by experience;
however an explanation for this has not yet been given in the literature.
Other question is whether there is any difference in the cancer location between young
and old patients? According to the results there is no difference in the spatial distribution of
cancer among these groups of people. This analysis should be completed with other clin-
ical parameters such as PSA in order to understand the aggressiveness of cancer in young
people. A larger database is required to perform a multivariate analysis.
Also is important to answer, where is more likely to appear cancer in its early stages?
i.e. when the tumor appear where is it more likely to be located? Based on the results
obtained, prostate cancer is more likely to appear in the posterior part (cancer percentage
less than 10% of the whole prostate, see Figure 5.5) and the area closest to the rectum, and
then it spreads to the rest of the gland. This result emphasizes the value of DRE in the early
stages because it is more probable that the cancer starts in the area to which the doctor has
access.
One of the most important questions to the scientific community both clinical and aca-
demic is the understanding of PSA as a marker and determines whether the value of PSA
cutoff is more appropriate. In the USA and Peru, the PSA value of 4 ng/ml has become
widely used as a decision limit to identify prostate cancer in its early stages, but this value
does not mean that the disease is advanced enough to extract the prostate gland. The prob-
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ability of finding prostate cancer with a serum PSA of 4 ng/ml is about 20% [45]. In our
database, the total number of patients that have PSA less than 4 ng/ml is 14 of 58 (24.14%)
so, it requires a greater number of patients to have a significant sample of men with PSA
less than 4 ng/ml.
The value of 5 ng/ml was used as cutoff to develop two spatial distributions to com-
pare two populations and find significant differences. The value of 5 ng/ml was chosen
because of the PSA concentrations in serum increase with age [66] and the average age of
our database is 59.8 ± 5.472 ranging from 48.5 to 72.8 years old. According to our results
prostate cancer has a significant difference in the right zone of the prostate in patients with
PSA over than and less than 5 ng/ml.
Currently, there is no consensus on the selection of the cutoff [67]. A low PSA cutoff
(0.2 − 2 ng/ml) can cause unnecessary treatment which results in an overmedication affect-
ing the quality of life on the patients. On the other hand, high PSA cutoff value (> 7ng/ml)
can cause the treatment is not longer enough to remove the cancer. The PSA cutoff value
should be studied in conjunction with other pathological variables as age and prostate vol-
ume. This tool could be used to set various PSA cutoffs and determine if there is a critical
value of PSA and set this cutoff for future research in order to understand the disease.
An analysis of 12 zones of the prostate was proposed for a better understanding of the
spatial distribution of the tumor. These zones are chosen according clinical conventions,
and the significant differences in each zone are calculated. The results from the statistical
analysis show that the anterior right zones have more significant difference (> 34%) for PSA
greater than 5 ng/ml against PSA less than 5 ng/ml; there is also a significantly higher can-
cer distribution (77.71%) in the base anterior right zone for Positive and negative capsule
penetration.
An analysis by zones based on the prostate anatomical region: Transition Zone, Periph-
eral zone, Central Zone and Fibro muscular stroma should be more clinically relevant than
an overall analysis of the whole prostate. The developed tool could provide this analysis
using a previously segmented gland by an expert radiologist to divide the regions.
A limitation of this study is the small database: 58 prostate specimens are not sufficient
to represent correctly the spatial distributions of the cancer. This amount of samples limits
our ability to perform a multivariate analysis. A multivariate analysis would allow us to
find and study relationships between populations with more than one requirement. The tool
developed in this thesis can make the analysis with more the one clinical parameter, e. g.
the analysis for men older than 80 years old and with PSA greater than 5 ng/ml.
A larger database is needed to improve statistical validity of the test. A solution would
be multi-institutional studies and data sharing processes; a larger sample size could give
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a more realist distribution independently of the acquisition process with less bias. We are
planning to validate our result and increase the population using the database of the Sec-
tion of Biomedical Image Analysis (SBIA), University of Pennsylvania, Philadelphia, USA.
To summarize, the main contributions of this work are the image processing methodol-
ogy to develop the spatial distribution from a database of whole mount histology sections,
and the statistical analysis to compare two spatial distributions based on differences of pro-
portions.
Bibliography
[1] Mayo Clinic, “Prostate cancer, transrectal biopsy of the prostate.,” Tech. Rep., Mayo
Foundation for Medical education and research., 8 2012.
[2] Betrouni N., Iancu A., Puech P., Mordon S., and Makni N., “Prostatlas: a digital
morphologic atlas of the prostate.,” European Journal of Radiology, vol. 81, no. 9, pp.
1969 – 1975, 2012.
[3] Taylor L. S., Porter B. C., Nadasdy G., di SantAgnese P. A., Pasternack D., Wu Z.,
Baggs R. B., Rubens D. J., and Parker K. J., “Three-dimensional registration of
prostate images from histology and ultrasound.,” Ultrasound in Medicine & Biology,
vol. 30, no. 2, pp. 161 – 168, 2004.
[4] Zhu Y., Williams S., and Zwiggelaar R., “Computer technology in detection and
staging of prostate carcinoma: A review.,” Medical Image Analysis, vol. 10, no. 2, pp.
178 – 199, 2006.
[5] Sobin L. H., Gospodarowicz M. K., and Wittekind Ch., TNM classification of Malig-
nant tumours., Wiley-Blackwell, seventh edition, 2009.
[6] Stott P., “The prostate : small gland, big problem.,” International Journal of Clinical
Practice, vol. 58, no. 6, pp. 647–647, 2004.
[7] Ablin R. J. and Mason M. D., Metastasis of prostate cancer., vol. 10, Springer; 1
edition, 2007.
[8] Oficina General de Planteamiento y Presupuesto, “Instituto nacional de enfermedades
neoplsicas organismo publico ejecutor: Plan operativo institucional 2011.,” Tech.
Rep., Instituto Nacional de Enfermedades Neoplsicas, 2011.
[9] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, and Parkin DM., “Globocan
2008 v1.2, cancer incidence and mortality worldwide: Iarc cancerbase no. 10 [in-
ternet].lyon, france: International agency for research on cancer; 2010.,” may 2008.
[10] Jewett H. J., “Significance of the palpable prostatic nodule.,” Journal of the American
Medical Association, vol. 160, no. 10, pp. 838–839, 1956.
[11] Schroder F. H., Kruger A. B., Rietbergen J., Kranse R., Maas P., Beemsterboer P.,
and Hoedemaeker R., “Evaluation of the digital rectal examination as a screening
44
BIBLIOGRAPHY 45
test for prostate cancer.,” JNCI Journal of the National Cancer Institute, vol. 90, pp.
1817–1823, 1998.
[12] Tang J., Yang J. C., Li Y., Li J., and Shi H., “Peripheral zone hypoechoic lesions of the
prostate.,” Journal of Ultrasound in Medicine, vol. 26, no. 12, pp. 1671–1679, 2007.
[13] Flanigan R. C.and Catalona W. J., Richie J. P., Ahmann F. R., Hudson M. A.,
Scardino P. T., deKernion J. B., Ratliff T. L., Kavoussi L. R., and Dalkin B. L., “Accu-
racy of digital rectal examination and transrectal ultrasonography in localizing prostate
cancer.,” The Journal of urology, vol. 152, no. 5, pp. 1506–1509, 1994.
[14] Bauer J. J., Zeng J., Weir J., Zhang W., Sesterhenn I. A., Connelly R. R., Mun S.
K., and Moul J. W., “Three-dimensional computer-simulated prostate models: lateral
prostate biopsies increase the detection rate of prostate cancer.,” Urology, vol. 53, no.
5, pp. 961 – 967, 1999.
[15] Bauer J. J., Zeng J., Zhang W., McLeod D. G., Sesterhenn I. A., Connelly R. R.,
Mun S. K., and Moul J. W., “3-d computer visualization and interactive prostate biopsy
simulation leads to an improved systematic technique for the detection of prostate
cancer: clinical correlation.,” Studies In Health Technology And Informatics, vol. 70,
pp. 20–25, 2000.
[16] Bauer J. J., Zeng J., Zhang W., McLeod D. G., Sesterhenn I. A., Connelly R. R.,
Mun S. K., and Moul J. W., “Lateral biopsies added to the traditional sextant prostate
biopsy pattern increases the detection rate of prostate cancer.,” Prostate cancer and
prostatic diseases, vol. 3, no. 1, pp. 43–46, 2000.
[17] Zeng J., Bauer J., Zhang W., Sesterhenn I., Connelly R., Lynch J., Moul J., and Mun S.
K., “Prostate biopsy protocols: 3d visualization-based evaluation and clinical correla-
tion.,” Computer Aided Surgery, vol. 6, no. 1, pp. 14–21, 2001.
[18] Zeng J., Bauer J. J., and Mun S. K., “Modeling and mapping of prostate cancer.,”
Computers & Graphics, vol. 24, no. 5, pp. 683 – 694, 2000, Dynamic Medical Visu-
alization (special topic).
[19] Zeng J., Bauer J., Sofer A., Yao X., Opell B., Zhang W., Sesterhenn I., Moul J., Lynch
J., and Mun S., “Distribution of prostate cancer for optimized biopsy protocols.,” in
Medical Image Computing and Computer-Assisted Intervention MICCAI 2000, Scott
Delp, Anthony DiGoia, and Branislav Jaramaz, Eds., vol. 1935 of Lecture Notes in
Computer Science, pp. 141–177. Springer Berlin / Heidelberg, 2000.
[20] Shen D., Lao Z., Zeng J., Herskovits E., Fichtinger G., and Davatzikos C., “A sta-
tistical atlas of prostate cancer for optimal biopsy.,” in Medical Image Computing
and Computer-Assisted Intervention MICCAI 2001, Wiro Niessen and Max Viergever,
Eds. 2001, vol. 2208 of Lecture Notes in Computer Science, pp. 416–424, Springer
Berlin / Heidelberg.
BIBLIOGRAPHY 46
[21] Shen D., Lao Z., Zeng J., Herskovits E. H., Fichtinger G., and Davatzikos C., “Statis-
tically optimized biopsy strategy for the diagnosis of prostate cancer.,” in Computer-
Based Medical Systems, 2001. CBMS 2001. Proceedings. 14th IEEE Symposium on,
2001, pp. 433 –438.
[22] Opell M. B., Zeng J., Bauer J. J., Connelly R. R., Zhang W., Sesterhenn I. A., Mun S.
K., Moul J. W., and Lynch J. H., “Investigating the distribution of prostate cancer using
three-dimensional computer simulation.,” Prostate Cancer and Prostatic Diseases,
vol. 5, no. 3, pp. 204–8, 2002.
[23] Sofer A., Zeng J., and Mun S. K., “Optimal biopsy protocols for prostate cancer.,”
Annals of Operations Research, vol. 119, pp. 63–74, 2003.
[24] Shen D., Lao Z., Zeng J., Zhang W., Sesterhenn I. A., Sun L., Moul J. W., Her-
skovits E. H., Fichtinger G., and Davatzikos C., “Optimized prostate biopsy via a
statistical atlas of cancer spatial distribution.,” Medical Image Analysis, vol. 8, no. 2,
pp. 139 – 150, 2004.
[25] Zeng J., Kaplan C., Bauer J., Zhang W., Sesterhenn I., Moul J., and Mun S. K., “Visu-
alization and evaluation of prostate needle biopsy.,” in The First International Confer-
ence on Medical Image Computing and Computer-Assisted Intervention, WilliamM.
Wells, Alan Colchester, and Scott Delp, Eds., vol. 1496 of Lecture Notes in Computer
Science, pp. 285–292. Springer Berlin Heidelberg, 1998.
[26] Chen M. E., Troncoso P., Johnston D., Tang K., and Babaian R. J., “Optimization of
prostate biopsy strategy using computer based analysis.,” The Journal of urology, vol.
158, no. 6, pp. 2168–2175, 1997.
[27] Chen M. E., Troncoso P., Tang K., Babaian R. J., and Johnston D., “Comparison of
prostate biopsy schemes by computer simulation.,” Urology, vol. 53, no. 5, pp. 951 –
960, 1999.
[28] Chen M. E., Troncoso P., Johnston D., Tang K., and Babaian R. J., “Prostate cancer
detection: relationship to prostate size.,” Urology, vol. 53, no. 4, pp. 764 – 768, 1999.
[29] Babaian R. J., Toi A., Kamoi K., Troncoso P., Sweet J., Evans R., Johnston D., and
Chen M., “A comparative analysis of sextant and an extended 11-core multisite di-
rected biopsy strategy.,” The Journal of Urology, vol. 163, no. 1, pp. 152 – 157, 2000.
[30] Loch T. and Chen M. E., “Computer simulation of prostate biopsies.,” European
urology, vol. 1, pp. 47 – 51, 2002.
[31] Daneshgari F., Taylor G. D., Miller G. J., and Crawford E. D., “Computer simulation
of the probability of detecting low volume carcinoma of the prostate with six random
systematic core biopsies.,” Urology, vol. 45, no. 4, pp. 604 – 609, 1995.
[32] Crawford E. D., Hirano D., Werahera P. N., Lucia M. S., Deantoni E. P., Daneshgari
F., Brawn P. N., Speights V. O., Stewart J. S., and Miller G. J., “Computer modeling
BIBLIOGRAPHY 47
of prostate biopsy: Tumor size and location-not clinical significance-determine cancer
detection.,” The Journal of Urology, vol. 159, no. 4, pp. 1260 – 1264, 1998.
[33] Kawata N., Miller G. J., Crawford E. D., Torkko K. C., Stewart J. S., Lucia M. S.,
Miller H. L., Hirano D., and Werahera P. N., “Laterally directed biopsies detect more
clinically threatening prostate cancer: Computer simulated results.,” The Prostate,
vol. 57, no. 2, pp. 118–128, 2003.
[34] Loughlin M., Carlbom I., Busch C., Douglas T., Egevad L., Frimmel H., Norberg M.,
Sesterhenn I., and Frogge J. M., “Three-dimensional modeling of biopsy protocols for
localized prostate cancer.,” Computerized Medical Imaging and Graphics, vol. 22, no.
3, pp. 229 – 238, 1998.
[35] Frimmel H., Egevad L., Bengtsson E., and Busch C., “Modeling prostate cancer
distributions.,” Urology, vol. 54, no. 6, pp. 1028 – 1034, 1999.
[36] Egevad L., Frimmel H., Mattson S., Bengtsson E., and Busch C., “Biopsy protocol
stability in a three-dimensional model of prostate cancer: changes in cancer yield after
adjustment of biopsy positions.,” Urology, vol. 54, no. 5, pp. 862 – 868, 1999.
[37] Egevad L., Frimmel H., Norberg M., Mattson S., Carlbom I., Bengtsson E., and
Busch C., “Three-dimensional computer reconstruction of prostate cancer from rad-
ical prostatectomy specimens: evaluation of the model by core biopsy simulation.,”
Urology, vol. 53, no. 1, pp. 192 – 198, 1999.
[38] Xuan J., Wang Y., Sesterhenn I., Moul J., and Mun S., “3-d model supported prostate
biopsy simulation and evaluation.,” in Medical Image Computing and Computer-
Assisted Interventation MICCAI 1998, William Wells, Alan Colchester, and Scott
Delp, Eds., vol. 1496 of Lecture Notes in Computer Science, pp. 358–367. Springer
Berlin / Heidelberg, 1998.
[39] Shen D. and Davatzikos C., “An adaptive-focus deformable model using statistical
and geometric information.,” Pattern Analysis and Machine Intelligence, IEEE Trans-
actions on, vol. 22, no. 8, pp. 906 –913, aug 2000.
[40] Shen D., Herskovits E. H., and Davatzikos C., “An adaptive-focus statistical shape
model for segmentation and shape modeling of 3-d brain structures.,” Medical Imag-
ing, IEEE Transactions on, vol. 20, no. 4, pp. 257 –270, april 2001.
[41] Ou Y., Shen D., Zeng J., Sun L., Moul J., and Davatzikos C., “Sampling the spa-
tial patterns of cancer: Optimized biopsy procedures for estimating prostate cancer
volume and gleason score.,” Medical Image Analysis, vol. 13, no. 4, pp. 609 – 620,
2009.
[42] McCormack M., “Canadian family physician.,” Prostate Cancer New serum tumor
marker for monitoring patients, vol. 38, pp. 1438–1440, june 1992.
BIBLIOGRAPHY 48
[43] Brawer M. K., Chetner M. P., Beatie J., Buchner D. M., Vessella R. L., and Lange P.
H., “Screening for prostatic carcinoma with prostate specific antigen.,” The Journal
of urology, vol. 147, pp. 841–5, 1992.
[44] Catalona W. J., Smith D. S., Ratliff T. L., and Basler J. W., “Detection of organ-
confined prostate cancer is increased through prostate-specific antigen-based screen-
ing.,” JAMA : the journal of the American Medical Association, vol. 270, pp. 948–54,
1993.
[45] Crawford E. D., DeAntoni E. P., Etzioni R., Schaefer V. C., Olson R. M., Ross C.
A., and The Prostate Cancer Education Council., “Serum prostate-specific antigen
and digital rectal examination for early detection of prostate cancer in a national
community-based program.,” Urology, vol. 47, no. 6, pp. 863 – 869, 1996.
[46] Mettlin C., Lee F., Drago J., and Murphy G. P., “The american cancer society national
prostate cancer detection project: findings on the detection of early prostate cancer in
2425 men.,” Cancer, vol. 67, no. 12, pp. 2949–58, 1991.
[47] Brawer M. K. and Kirby R., Prostate Specific Antigen., Marcel Dekker, 2001.
[48] Li-Ming Su MD., Early Diagnosis and Treatment of Cancer Series: Prostate Cancer.,
Saunders; 1 Har/Psc edition, November 2009.
[49] Egevad L., Engstrom K., and Busch C., “A new method for handling radical prosta-
tectomies enabling fresh tissue harvesting, whole mount sections, and landmarks for
alignment of sections.,” Journal Urology Pathology,, vol. 9, pp. 1728, 1998.
[50] George Wolberg, Digital Image Warping., IEEE Computer Society Press, 1990.
[51] Beier T. and Neely S., “Feature-based image metamorphosis.,” Computer graphics
and interactive techniques, vol. 2, pp. 35–42, 1992.
[52] Rafael C. Gonzalez and Richard E. Woods, Digital Image Processing (3rd Edition).,
Prentice-Hall, Inc., Upper Saddle River, NJ, USA, 2006.
[53] Otsu N., “A threshold selection method from gray-level histograms,” Systems, Man
and Cybernetics, IEEE Transactions on, vol. 9, no. 1, pp. 62 –66, jan. 1979.
[54] Ladak H. M., Mao F., Wang Y., Downey D. B., Steinman D. A., and Fenster A.,
“Prostate boundary segmentation from 2d ultrasound images.,” Medical Physics, vol.
27, no. 8, pp. 1777–88, 2000.
[55] Lobregt S. and Viergever M. A., “A discrete dynamic contour model.,” Medical
Imaging, IEEE Transactions on, vol. 14, no. 1, pp. 12 –24, mar 1995.
[56] Kels S. and Dyn N., “Reconstruction of 3d objects from 2d cross-sections with the
4-point subdivision scheme adapted to sets.,” Computers & Graphics, vol. 35, no. 3,
pp. 741 – 746, 2011.
BIBLIOGRAPHY 49
[57] Albu A. B., Beugeling T., and Laurendeau D., “A morphology-based approach for
interslice interpolation of anatomical slices from volumetric images.,” Biomedical
Engineering, IEEE Transactions on, vol. 55, no. 8, pp. 2022–2038, 2008.
[58] Csebfalvi B., Neumann L., Kanitsar A., and Groller E., “Smooth shape-based inter-
polation using the conjugate gradient method.,” Proceedings of vision, modeling, and
visualization., p. 12330, 2002.
[59] Lin W. C., Liang C. C., and Chen C. T., “Dynamic elastic interpolation for 3d medical
image reconstruction from serial cross sections.,” Medical Imaging, IEEE Transac-
tions on, vol. 7, no. 3, pp. 225 –232, sep 1988.
[60] Raya S. P. and Udupa J. K., “Shape-based interpolation of multidimensional objects.,”
Medical Imaging, IEEE Transactions on, vol. 9, no. 1, pp. 32 –42, mar 1990.
[61] Herman G.T., Zheng J., and Bucholtz C. A., “Shape-based interpolation.,” Computer
Graphics and Applications, IEEE, vol. 12, no. 3, pp. 69 –79, may 1992.
[62] Lee T. Y. and Wang W. H., “Morphology-based three-dimensional interpolation.,”
Medical Imaging, IEEE Transactions on, vol. 19, no. 7, pp. 711 –721, july 2000.
[63] McNeal J. E., Redwine E. A., and Stamey T. A., “Zonal distribution of prostatic adeno-
carcinoma. correlation with histologic.,” The American journal of surgical pathology,
vol. 12, no. 12, pp. 897–906, 1988.
[64] Erbersdobler A., Huhle S., Palisaar J., Graefen M., Hammerer P., Noldus J., and Hu-
land H., “Pathological and clinical characteristics of large prostate cancers predom-
inantly located in the transition zone.,” Prostate Cancer Prostatic Dis, vol. 5, pp.
279–84, 2002.
[65] Terry S. Yoo., Insight into images: principles and practice for segmentation, registra-
tion, and image analysis., AK Peters, first edition, 2004.
[66] Castaneda B., Wu S., Hoyt K., Baxter L., Yao J., Pasternack D., Strang J., Rubens D. J.,
and Parker K.J., “Application of nonrigid registration to validate detection of prostate
cancer using threedimensional sonoelastography.,” Proceedings of the Seventh Inter-
national Conference on the Ultrasonic Measurement and Imaging of Tissue Elasticity,
p. 62, 2008.
[67] David J.Sheskin, Parametric And Nonparametric Statistical Procedures Second Edi-
tion., Chapman & Hall/Crc, 2000.
